Schwab Charles Investment Management Inc. raised its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 42.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 381,916 shares of the biopharmaceutical company’s stock after purchasing an additional 114,623 shares during the period. Schwab Charles Investment Management Inc. owned 0.45% of Sangamo Therapeutics worth $5,729,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the stock. Blair William & Co. IL raised its position in shares of Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 500 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 832 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Sangamo Therapeutics in the 3rd quarter worth about $118,000. Virtu KCG Holdings LLC bought a new position in shares of Sangamo Therapeutics in the 2nd quarter worth about $124,000. Finally, Amalgamated Bank bought a new position in shares of Sangamo Therapeutics in the 3rd quarter worth about $158,000. 64.09% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on the company. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 24th. Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Barclays assumed coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Jefferies Group restated a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.83.
Shares of Sangamo Therapeutics Inc (NASDAQ SGMO) traded down $0.15 on Wednesday, hitting $20.80. The stock had a trading volume of 839,190 shares, compared to its average volume of 1,484,447. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. The firm has a market cap of $1,800.30, a P/E ratio of -30.14 and a beta of 3.16. Sangamo Therapeutics Inc has a 12 month low of $3.35 and a 12 month high of $21.90.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The company had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same period last year, the business posted ($0.27) EPS. equities research analysts predict that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.
In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $17.26, for a total value of $258,900.00. Following the transaction, the vice president now owns 13,015 shares of the company’s stock, valued at approximately $224,638.90. The disclosure for this sale can be found here. Insiders have sold a total of 58,433 shares of company stock valued at $979,696 in the last quarter. Company insiders own 5.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics Inc (SGMO) Shares Bought by Schwab Charles Investment Management Inc.” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/31/schwab-charles-investment-management-inc-increases-holdings-in-sangamo-therapeutics-inc-sgmo.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.